CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PHARMA-COG aims to create an integrated model to speed up drug development for multiple sclerosis, polycystic kidney disease, and Alzheimer's disease. By using a multidimensional matrix approach, it seeks to improve early decision-making on drug candidates and enhance cognitive function treatments.
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD.
The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision before entering phase II trials for both symptomatic treatment and disease modifiers approaches.
The h…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Marseille
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, LILLE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
Germany, Leipzig
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
